GDS Wealth Management Has $1.97 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

GDS Wealth Management grew its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 245.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,463 shares of the medical research company's stock after buying an additional 8,851 shares during the quarter. GDS Wealth Management's holdings in Natera were worth $1,973,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. boosted its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc lifted its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Quarry LP boosted its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after purchasing an additional 190 shares during the period. Covestor Ltd grew its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

NASDAQ:NTRA traded down $2.32 during midday trading on Friday, reaching $172.82. The stock had a trading volume of 857,965 shares, compared to its average volume of 1,331,850. The stock has a market capitalization of $22.82 billion, a P/E ratio of -98.19 and a beta of 1.66. Natera, Inc. has a 1-year low of $67.33 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm's fifty day simple moving average is $167.56 and its 200-day simple moving average is $140.02.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the previous year, the company posted ($0.95) earnings per share. The firm's revenue for the quarter was up 63.9% on a year-over-year basis. On average, equities research analysts forecast that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on NTRA. Craig Hallum lifted their target price on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Morgan Stanley lifted their price objective on Natera from $132.00 to $176.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th. TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. StockNews.com downgraded Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. Finally, Robert W. Baird boosted their price target on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $165.88.

Insiders Place Their Bets

In related news, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,728 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the completion of the transaction, the chief executive officer now directly owns 185,034 shares of the company's stock, valued at approximately $27,090,827.94. This trade represents a 2.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 312,394 shares of company stock valued at $52,333,520 in the last three months. Company insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.